Asset
IVONESCIMAB
SUMMIT THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05899608 | phase3 | active_not_recruiting | 2023-10-26 | 2028-12-31 | Summit Therapeutics | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients |
| NCT06767514 | phase3 | recruiting | 2025-02-27 | 2028-04-01 | Summit Therapeutics | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 |
| NCT06396065 | phase3 | active_not_recruiting | 2023-05-04 | 2025-04-12 | Summit Therapeutics | Phase III Study of AK112 for NSCLC Patients |
FDA applications (0)
This company has no applications containing this asset.